Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting
Lenka Novakova1, Marcus Henricsson2, Elias Björnson2
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Multiple Sclerosis and Related Disorders
|April 15, 2023
Summary
Cerebrospinal fluid sulfatide isoforms do not help distinguish multiple sclerosis (MS) disease courses. Measuring these sulfatide levels in CSF is not a useful biomarker for diagnosing or predicting progression in MS.
Area of Science:
- Neuroimmunology
- Biochemistry
- Clinical Diagnostics
Background:
- Multiple sclerosis (MS) is an immune-mediated central nervous system disorder characterized by demyelination.
- Sulfatides, glycosphingolipids vital for myelin sheath structure, are found in cerebrospinal fluid (CSF).
- CSF sulfatide levels may indicate demyelination, a key feature of MS.
Purpose of the Study:
- To investigate the diagnostic utility of CSF sulfatide isoform levels.
- To differentiate between various multiple sclerosis disease courses and phenotypes.
Main Methods:
- A cross-sectional study involving patients with relapsing-remitting MS (RRMS), primary progressive MS (PMS), and secondary progressive MS (SPMS), alongside healthy controls.
- Quantification of 20 distinct sulfatide isoforms in CSF using liquid chromatography-mass spectrometry.
Main Results:
- No significant differences in total CSF sulfatide concentrations or isoform distribution were observed among the study groups.
- CSF sulfatide levels were found to be independent of MS disease course, duration, age, and disability.
- No correlation was found between CSF sulfatide levels and time to conversion to secondary progressive MS.
Conclusions:
- CSF sulfatide isoforms do not possess diagnostic or prognostic value for identifying progressive forms of MS.
- The current findings suggest that CSF sulfatides are not suitable biomarkers for differentiating MS phenotypes.
